Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies

A small-molecule hemostatic agent for the reversal of direct oral anticoagulant–induced bleeding

“…Despite significant recent progress, the treatment of hemophilia is still challenging. Replacement therapies and other treatments all have several drawbacks, such as the risk of alloimmunization, the parenteral administration route, and the high cost [ [30] , [31] , [32] ]. HeMo might be hemostatically efficient enough to counterbalance a procoagulant factor deficiency and might therefore be a treatment option in hemophilia and other rare bleeding disorders lacking a specific treatment (eg, severe FV deficiency).…”